1. CRISPR基因编辑技术在疾病诊疗中的应用
2. 基于微流控芯片开发智能/响应性纳米药物
3. 声遗传学诊疗平台的构建

围绕基因编辑、纳米药物、生物材料和微流控技术开展交叉学科研究工作。以第一作者在Science Advances, Angewandte Chemie International Edition, Advanced Functional Materials, Small等期刊发表SCI论文9篇，申请国家发明专利8项，主持中国药科大学高层次人才引进项目 (No. 3150010169)。
1．基因编辑介导的肿瘤微环境重塑用于肿瘤治疗的研究
构建可基因编辑的生物正交纳米平台，利用CRISPR-Cas9基因编辑技术对肿瘤细胞进行了多靶点基因改造，结合化疗和化学动力学治疗，对肿瘤微环境进行重塑，激活肿瘤相关巨噬细胞的抗肿瘤活性，并抑制肿瘤细胞的抗吞噬信号表达，实现巨噬细胞对肿瘤的吞噬杀伤。(Angew. Chem. Int. Ed. 2023, 62, e202313968; Chem. Eur. J. 2024, 30, e202402485)
2. 基于微流控芯片高通量制备纳米药物的研究
设计并加工微流控芯片，将纳米药物制备过程中涉及的混合、交联、自组装等步骤集成至芯片中，开发一系列具有特殊结构的微流控芯片（双层鱼骨、弯钩阵列、缩扩螺旋、液滴芯片、滑动芯片），实现高通量、连续化的纳米药物制备。 (Sci. Adv. 2024, 10, eadn8695; Angew. Chem. Int. Ed. 2023, 62, e202302000; Lab Chip 2024, 24, 3521-3527; Nano Lett. 2024, 24: 1081-1089)
3. 智能纳米药物重编程肿瘤代谢增强肿瘤治疗的研究
开发一系列光、声、pH响应的生物功能材料，负载小分子药物及大分子蛋白，实现肿瘤部位的靶向递送和可控释放。重编程肿瘤细胞的糖代谢、氨基酸代谢以及脂代谢途径，逆转肿瘤异常代谢环境，提高治疗有效性并降低毒副作用。同时，能够对肿瘤组织进行特异性识别和成像，实现肿瘤诊疗一体化。(Adv. Funct. Mater. 2022, 32, 2110092; Small. 2025, 202412281; Chem. Commun. 2021, 57, 7581-7584; ChemBioChem 2025, 26, e202400807)

1.Shujun Feng‡, Yu Zhang‡*, Chunyuan Hou, Yuta Liu, Yanfeng Gao*, Yujun Song*, Jun Luo*. A temperature-responsive dual-hormone foam nanoengine improves rectal absorptivity of insulin-pramlintide for diabetes treatment. Sci. Adv. 2024, 10, eadn8695. (IF: 11.7)
2.Shujun Feng‡, Yu Zhang‡, Yanfeng Gao‡, Yuta Liu, Yanyi Wang, Xin Han, Tao Zhang, Yujun Song*. A gene-editable palladium-based bioorthogonal nanoplatform facilitates macrophage phagocytosis for tumor therapy. Angew. Chem. Int. Ed. 2023, 62, e202313968. (IF: 16.1)
3.Shujun Feng‡, Chunyuan Hou‡, Yu Zhang‡, Nan Han, Bin Zhu, Yujun Song*, Minghui Lu*, Jun Luo*. A biological channel-inspired ultrasound-responsive metabolism nanoswitch for unleashing cancer sonometabolism therapy. Small. 2025. Accept (IF: 13.0)
4.Shujun Feng‡, Yu Zhang‡, Yanyi Wang‡, Yanfeng Gao*, Yujun Song*. Harnessing gene editing technology for tumor microenvironment modulation: an emerging anticancer strategy. Chem. Eur. J. 2024, 30, e202402485. (IF: 3.9)
5.Yu Zhang‡, Shujun Feng‡, Getian Hu, Tianliang Fang, Deqiao Xie, Qiangbing Lu, Yurui Xu*, Lida Shen*, Xinghai Ning*. An adenovirus-mimicking photoactive nanomachine preferentially invades and destroys cancer cells through hijacking cellular glucose metabolism. Adv. Funct. Mater. 2022, 32, 2110092. (IF: 18.5)
6.Yanping Wang‡, Shujun Feng‡, Xuyuan Wang‡, Chungui Tao, Yuta Liu, Yanyi Wang, Yanfeng Gao*, Jinsong Zhao*, Yujun Song*. Microfluidic synthesis of hemin@ZIF-8 nanozyme with applications in cellular reactive oxygen species detection and anticancer drug screening. Lab Chip 2024, 24, 3521-3527. (IF: 6.1)
7.Yu Zhang‡, Shujun Feng‡, Xia Meng, Jun Luo, Yurui Xu* and Xinghai Ning*. Identifying urotropine derivatives as co-donors of formaldehyde and nitric oxide for improving antitumor therapy. Chem. Commun. 2021, 57, 7581-7584. (IF: 4.3)
8.Jianmei Chen‡, Shujun Feng‡, Yurui Xu, Xinyu Huang, Jikang Zhang, Jiao Chen, Xueying An, Yu Zhang*, Xinghai Ning*. Discovery and characterization of a novel peptide inhibitor against influenza neuraminidase. RSC Med. Chem. 2020, 11, 148-154. (IF: 4.1)
9.Anyun Wang‡, Xinli Liu‡, Shujun Feng‡, Yanping Wang, Yujun Song*, Yanfeng Gao*. Synthesis and biomedical applications of covalent organic frameworks for disease diagnosis and therapy. ChemBioChem 2025, 26, e202400807. (IF: 2.6)